FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB	APP	ROV	Ά
-----	-----	-----	---

OMB Number:	3235-0287
Estimated average burden	
ha nav saananaa.	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

purchase or sale of issuer that is inten	e conditions of Rule							
(Last) C/O APIMEDS	s of Reporting Persor C. (First) PHARMACEUTIO STREET, 2ND F	(Middle) CALS US, INC.	2. Issuer Name and Ticker or Trading Symbol Apimeds Pharmaceuticals US, Inc. [APUS] 3. Date of Earliest Transaction (Month/Day/Year) 05/16/2025	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give title Other (specify below) Chief Executive Officer				
(Street) HOPEWELL (City)	NJ (State)	08425 (Zip)	If Amendment, Date of Original Filed (Month/Day/Year) ——	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

or coourny (mounts)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.		4. Securities Ac Disposed Of (D			5. Amount of Securities Beneficially Owned Following Reported	or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount (A) or (D) Price		Transaction(s) (Instr. 3 and 4)		(111341. 4)	
Common Stock, par value \$0.01 per share	05/16/2025		A		750,000	A	\$0	750,000	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (li 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	Ownership Form: Direct (D)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock option (right to buy)	\$1.81	05/16/2025		A		347,279		(1)	05/16/2035	Common Stock, par value \$0.01 per share	347,279	\$0	347,279	D	

Explanation of Responses:

1. Forty percent (40%) of the options vested immediately upon grant, and the remainder will vest in three equal annual installments beginning on 05/16/2026. The reporting person has agreed not to sell any shares underlying the options, even if exercised, for a period of three years from the date of grant.

/s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact 05/20/2025

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.